Furthermore, this study reveals the mechanism by which DJD can treat IDD by regulating the MAPK pathway: Quercetin targets AKT1, TP53, ERBB2, MYC, IL1B, CHUK, IGF2, RASA1, MET, and RPS6KA3; Kaempferol targets AKT1, INSR, and FLT3; Beta-Sitosterol targets TGFB1; Yangambin targets CACNA1S; and Methylicosa-11,19-dienoate targets PDGFRA. This evidence concerns the gene MET and intervertebral disk degenerative disorder.